Four Members of Congress Receive the 2001 Paul E. Tsongas Award

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 6
Volume 10
Issue 6

WASHINGTON-Four members of Congress received the 2001 Paul E. Tsongas Memorial Award for their contributions to forwarding cancer research and awareness of the disease. This year’s honorees were Sen. Edward M. Kennedy (D-Mass), Sen. Mike DeWine (R-Ohio), Rep. C. W. Bill Young (R-Fla), and Rep. Lois Capps (D-Calif).

WASHINGTON—Four members of Congress received the 2001 Paul E. Tsongas Memorial Award for their contributions to forwarding cancer research and awareness of the disease. This year’s honorees were Sen. Edward M. Kennedy (D-Mass), Sen. Mike DeWine (R-Ohio), Rep. C. W. Bill Young (R-Fla), and Rep. Lois Capps (D-Calif).

The annual Tsongas award recognizes "outstanding legislative leadership and commitment in support of health care issues that result in improving the quality of life for all Americans."

It is presented by the Lymphoma Research Foundation of America and named for the late Sen. Paul Tsongas (D-Mass), who served as the group’s honorary chair from its inception until his death in 1997 from complications associated with his treatment for lymphoma.

The awards were presented at a Capitol Hill reception. Only Sen. Kennedy was able to attend the ceremony (see photograph). In his acceptance remarks, Sen. Kennedy noted that his son, Rep. Patrick J. Kennedy (D-RI), who was in the audience, received the Tsongas award last year.

"You see, he’s learning from me," Patrick Kennedy quipped to laughter and applause. "He’s coming along nicely."

In a more serious moment, Sen. Kennedy noted the successful work of the Human Genome Project and its potential. "When we look at the possibilities today, I firmly believe that this period of our time will be known as the time of the life sciences," he said. "It is the life sciences that are going to mark the way toward finding important paths for dealing with these challenges in lymphoma."

The senator, whose son Edward suffered from osteosarcoma as a child, also praised the efforts of advocacy groups like the Lymphoma Research Foundation. "I am all for what the government, the NIH, can do, and there is nothing that can replace that," Senator Kennedy said. "But the work this foundation does—in terms of the research it funds and in getting information out—is something that is enormously important, and I hope you know that."

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content